Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70771-1523-09 70771-1523 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68001-0487-06 68001-0487 CAPECITABINE CAPECITABINE 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 22, 2021 In Use
42658-0019-01 42658-0019 Daunorubicin hydrochloride Daunorubicin Hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jan. 20, 2020 In Use
43598-0344-10 43598-0344 Imatinib Imatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 13, 2018 In Use
43598-0344-30 43598-0344 Imatinib Imatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 13, 2018 In Use
43598-0344-31 43598-0344 Imatinib Imatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 15, 2020 In Use
43598-0344-90 43598-0344 Imatinib Imatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 13, 2018 In Use
43598-0345-05 43598-0345 Imatinib Imatinib 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 13, 2018 In Use
43598-0345-30 43598-0345 Imatinib Imatinib 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 13, 2018 In Use
43598-0345-31 43598-0345 Imatinib Imatinib 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 15, 2020 In Use
43598-0345-90 43598-0345 Imatinib Imatinib 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 13, 2018 In Use
43598-0389-57 43598-0389 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous April 22, 2019 In Use
43598-0865-60 43598-0865 Bortexomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Nov. 1, 2019 In Use
43817-0906-01 43817-0906 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Subcutaneous May 6, 2019 In Use
47335-0323-40 47335-0323 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
47335-0475-13 47335-0475 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2016 In Use
47335-0475-64 47335-0475 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2016 In Use
47335-0475-83 47335-0475 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2016 In Use
47335-0475-88 47335-0475 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2016 In Use
47335-0890-21 47335-0890 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 13, 2014 In Use
47335-0890-72 47335-0890 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 13, 2014 In Use
47335-0890-74 47335-0890 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 13, 2014 In Use
47335-0890-75 47335-0890 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 13, 2014 In Use
47335-0890-80 47335-0890 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 13, 2014 In Use
47335-0890-87 47335-0890 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 13, 2014 In Use

Found 10,000 results in 5 millisecondsExport these results